Amnestix

Amnestix, is an early stage biotech company founded in 2006, which focuses on novel therapeutics for improving memory associated with a variety of human diseases. 

The company was founded on the discoveries of Dietrich Stephan, PhD., Director of the Neurogenomics Division, his associate, Matthew Huentelman, PhD., at the Translational Genomics Institute in Phoenix, Arizona, and collaborators at the University of Zurich.

Working with Amnestix Chief Executive Officer Karoly Nikolich, PhD, the newly formed company is developing small-molecule drugs for memory-related disorders. The seed funding for Amnestix was provided by Brain Trust Accelerator Fund, L.P.

The company was successfully acquired by Sygnis, a leading biotechnology company in Europe in June 2008.

NeuroFluidics

Neurofluidics is an early stage device company which develops novel, targeted and logical treatment approaches for patients suffering from a variety of neurological disorders.

Satoris

Satoris is an early stage molecular diagnostics company which focuses on developing blood-based tests for neurodegenerative diseases. The company is committed to developing and commercializing neurodiagnostic tests that yield the earliest, most accurate, and most clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective.